<DOC>
	<DOCNO>NCT00252655</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Sirolimus ( Rapamune ) improve function transplant kidney , without increase risk acute rejection adverse side effect , compare Tacrolimus ( Prograf ) . We hypothesize Sirolimus , one component long-term steroid-free immunosuppressive regimen , effective maintain low incidence acute rejection short- long-term graft survival comparable Tacrolimus better graft function high-risk African-American renal transplant population immediate graft function .</brief_summary>
	<brief_title>Use Sirolimus vs. Tacrolimus For African-American Renal Transplant Recipients</brief_title>
	<detailed_description>It repeatedly demonstrate African-American renal allograft recipient bad graft outcome compare Caucasians . This attribute various immunologic non-immunologic factor , include great rate acute rejection , resistance standard dos calcineurin inhibitor ( CNIs ) corticosteroid , different pharmacokinetic pharmacodynamic profile , noncompliance . It therefore suggest quadruple immunosuppression , include antilymphocyte antibody induction , use high-risk population improve graft survival . CNIs currently mainstay immunosuppressive regimen . Tacrolimus show significantly effective Cyclosporine A prevent acute rejection . As result , Tacrolimus become CNI choice prevent acute rejection , produce similar graft survival rate one year , high creatinine clearance . However , report examine efficacy Sirolimus improve renal function side effect profile compare Tacrolimus renal allograft recipient , particularly African-Americans immediate graft function steroid-free environment .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>AfricanAmerican living deceaseddonor renal transplant least 18 year age current historical negative crossmatch demonstrate urine output &gt; 60 ml/hr fall serum creatinine &gt; 20 % /day first 48 hour posttransplant , without need dialysis . Unwillingness participate study Current PRA &gt; 20 % Noncompliance protocol followup visit Those need maintenance steroid due underlying disease Known hypersensitivity study drug Pregnancy Pretransplant leukopenia , thrombocytopenia , hypercholesterolemia , hypertriglyceridemia despite optimal medical therapy HIV positive recipient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>